BJU International
BJU International
3 years ago

Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer

Matthew R. Cooperberg, Christopher L. Amling, William J. Aronson, Amanda De Hoedt, Lauren E. Howard, Daniel Moreira, Martha K. Terris, Stephen J. Freedland, Christopher J. Kane
Objectives To examine whether prostate-specific antigen doubling time (PSADT) correlates with metastases, all-cause mortality (ACM), and prostate cancer-specific mortality (PCSM) and to identify PSADT thresholds that can be used clinically for risk stratification in men with M0 castration-resistant prostate cancer (CRPC). Materials and Methods We collected data on 441 men with M0 CRPC in 2000–2015 at five Veterans Affairs hospitals. Cox models were used to test the association between log-transformed PSADT and the development of metastasis, ACM and PCSM. To identify thresholds, we categorized PSADT into 3-month groups and then combined groups with similar hazard ratios (HRs). Results The median (interquartile range) follow-up was 28.3 (14.7–49.1) months. As a continuous variable, PSADT was associated with metastases, ACM and PCSM (HR 1.40–1.68, all P < 0.001). We identified the following PSADT thresholds: <3 months; 3–8.9 months; 9–14. months; and ≥15 months. As a categorical variable, PSADT was associated with metastases, ACM and PCSM (all P < 0.001). Specifically, PSADT <3 months was associated with an approximately ninefold increased risk of metastases (HR 8.63, 95% CI 5.07–14.7) and PCSM (HR 9.29, 95% CI 5.38–16.0), and a 4.7-fold increased risk of ACM (HR 4.71, 95% CI 2.98–7.43) on multivariable analysis compared with PSADT ≥15 months. The median times to metastasis for patients with PSADT <3, 3–8.9, 9–14.9 and ≥15 months were 9, 19, 40 and 50 months, respectively. Conclusion Prostate-specific antigen doubling time was a strong predictor of metastases, ACM and PCSM in patients with M0 CRPC. As with patients at earlier disease stages, <3, 3–8.9, 9–14.9 and ≥15 months are reasonable PSADT thresholds for risk stratification in men with M0 CRPC. These thresholds can be used for selecting high-risk men for clinical trials.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bju.13856

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.